NOT.BE - NOVARTIS NAM. SF 0,50

Berlin - Berlin Delayed Price. Currency in EUR
70.78
-0.28 (-0.39%)
At close: 6:45PM CET
Stock chart is not supported by your current browser
Previous Close71.06
Open70.96
Bid0.00 x 87300
Ask0.00 x 10000
Day's Range70.68 - 71.02
52 Week Range65.89 - 77.69
Volume185
Avg. Volume31
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense
    Investor's Business Daily6 hours ago

    Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense

    Celgene could comfortably spend $11 billion to acquire Juno, an analyst said Wednesday after rumors circulated that the two biotechs could be in merger talks.

  • Reuters17 hours ago

    Novartis's Kymriah wins speedy reviews in U.S., Europe

    Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment. Kymriah, already approved for treatment of children and young adults with r/r B-cell acute lymphoblastic leukemia (ALL), will now get speedy scrutiny by the U.S. Food and Drug Administration for use against relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in adults, the company said in a statement. In addition, the European Medicines Agency granted an accelerated assessment for Kymriah in children and young adults with ALL.

  • Novartis (NVS) Announces Acceptance of Humira BLA by the FDA
    Zacksyesterday

    Novartis (NVS) Announces Acceptance of Humira BLA by the FDA

    Novartis (NVS) Biologics License Application (BLA) for the proposed biosimilar of blockbuster drug Humira was accepted by the FDA under the 351 (k) pathway.

  • Momenta Pharmaceuticals, Inc. Continues Its Rollercoaster Ride
    Motley Fool5 days ago

    Momenta Pharmaceuticals, Inc. Continues Its Rollercoaster Ride

    At least it's on the upswing.

  • American City Business Journals7 days ago

    Novartis becomes latest big-name collaborator for Chapel Hill company

    On the heels of collaborations with Bristol-Myers Squibb (BMY) and Allergan (AGN), Chapel Hill-based clinical data company Target PharmaSolutions’ latest collaboration is with Novartis (NVS). Novartis will collaborate with Target on its NASH study, focused on patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

  • Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
    Zacks7 days ago

    Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar

    Novartis (NVS) announced the initiation of a trial on the biosimilar version of Cosentyx which will compare the drug to its proposed biosimilar for the treatment of ankylosing spondylitis.

  • GuruFocus.com8 days ago

    5 Companies Hit 52-Week Highs

    Multiple companies have managed to reach yearly highs

  • Cancer Space Update: New Regulatory Status for 3 Major Drugs
    Zacks12 days ago

    Cancer Space Update: New Regulatory Status for 3 Major Drugs

    Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.

  • Why Juno Therapeutics Stock Cooled Off in December
    Motley Fool13 days ago

    Why Juno Therapeutics Stock Cooled Off in December

    Juno's year-long rally came to an abrupt halt last month on concerns that it won't be able to catch up to the leaders in CAR-T.

  • Novartis Gets Second Breakthrough Designation for Kisqali
    Zacks13 days ago

    Novartis Gets Second Breakthrough Designation for Kisqali

    Novartis (NVS) announces that the FDA has granted the second breakthrough designation to breast cancer drug, Kisqali, for the initial endocrine-based treatment of pre- or peri-menopausal women with HR+/HER2- advanced or metastatic breast cancer.

  • 3 Biggest Breakthroughs in Cancer Treatment in 2017
    Motley Fool18 days ago

    3 Biggest Breakthroughs in Cancer Treatment in 2017

    This year has seen a number of major breakthroughs in cancer care. Here is a look at three of the most significant.

  • Barrons.com19 days ago

    [$$] Glaxo: Expect a Speedy Recovery

    Advair, the world’s top-selling respiratory drug, will probably face generic competition in the U.S. beginning in 2018. It’s the biggest moneymaker for United Kingdom-based GlaxoSmithKline , whose earnings estimates have been sliding, and whose shares have tumbled since the summer. To see why, look back to Pfizer (PFE) seven years ago, on the eve of Lipitor’s patent expiration.

  • Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates from Novartis
    Zacks19 days ago

    Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates from Novartis

    Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.

  • Reuters21 days ago

    Swiss stocks - Factors to watch on Dec 28

    ZURICH, Dec 28 (Reuters) - The Swiss blue-chip SMI was seen opening 0.2 percent higher at 9,452 points on Thursday, according to premarket indications by bank Julius Baer . The following are some of the ...

  • Reuters21 days ago

    BRIEF-China Pioneer Pharma Enters Agreement For Sale Of Ophthalmic Pharmaceutical Products

    Dec 28 (Reuters) - China Pioneer Pharma Holdings Ltd : * CO ‍ENTERED AGREEMENT WITH ALCON AND AFFILIATE BEIJING NOVARTIS PHARMACEUTICAL CO FOR SALE OF OPHTHALMIC PHARMACEUTICAL PRODUCTS * PARTIES AGREE ...

  • Reuters21 days ago

    BRIEF-Luye Pharma Group‍ Announces Update on Patent Litigation Regarding Rivastigmine 1 Day Patch

    Dec 28 (Reuters) - Luye Pharma Group Ltd: * COURT OF APPEAL FOR DISTRICT OF MUNICH, GERMANY DISMISSES APPEAL FROM NOVARTIS AG AS CLAIMANT IN PATENT INFRINGEMENT LAWSUIT * ‍PATENT INFRINGEMENT LAWSUIT ON ...

  • Gadfly's 2017 Toast to the Departed
    Bloomberg21 days ago

    Gadfly's 2017 Toast to the Departed

    Some business stories have happy endings; these didn't quite.

  • Reuters26 days ago

    Allergan says court affirms patent loss to Sandoz on eye drug

    Allergan Inc said on Friday that it had lost its appeal in a patent battle with Novartis AG over its Sandoz division's rival version of Allergan's Combigan eye drug and said it would file a petition to for a rehearing of the case. Allergan said the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the Eastern District of Texas' earlier decision that the Sandoz rival did not infringe two of Allergan's patents and reversed a decision on a third patent in favor of Novartis.

  • Associated Press27 days ago

    California court exposes drug makers to additional liability

    SAN FRANCISCO (AP) — A sharply divided California Supreme Court ruled Thursday that pharmaceutical companies can be held liable for warning labels on generic versions of drugs they once made even after they've sold the drugs to other companies and stopped manufacturing them.

  • Reuters27 days ago

    California court says Novartis can be sued over generic drug injuries

    California's top court on Thursday opened the door for consumers to sue Novartis AG and other makers of brand-name pharmaceutical products over injuries blamed on generic versions of the drugs manufactured by other companies. The California Supreme Court's ruling broke with decisions nationally to the contrary and created exposure for brand-name drugmakers who could be sued in the state for failing to warn users about the risks of cheaper, generic versions of their drugs. Leslie Brueckner, the plaintiffs' lawyer, said the decision was the only one currently by a state's top court to favor consumers of generic drugs, who legally cannot sue generic drugmakers for not warning about their products' risks.

  • Forbes27 days ago

    5 Milestones Of 2017 In The War On Cancer

    From personalized CAR-T cell therapies to novel combination treatments, 2017 has been a banner year in cancer research.

  • 3 Top Generic Drug Stocks to Consider Buying Now
    Motley Fool28 days ago

    3 Top Generic Drug Stocks to Consider Buying Now

    Want to cash in on the pharmaceutical boom? Generic drugs add to the arguments for giving Pfizer, Novartis and Mylan a closer look.

  • Novartis (NVS) Oncology Head Strigini to Step Down by Dec. 31
    Zackslast month

    Novartis (NVS) Oncology Head Strigini to Step Down by Dec. 31

    Novartis (NVS) is at a transitional stage as the CEO of its oncology segment will step down by the end of year. The company's CEO is also going to step next year.

  • MarketWatchlast month

    Ultragenyx sells rare drug voucher for $130 mln to Novartis

    Ultragenyx Pharmaceutical Inc. has agreed to sell a Food and Drug Administration-issued priority review voucher to Novartis AG for $130 million, the company said on Monday. Ultragenyx shares rose 3.4% ...

  • CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More
    Zackslast month

    CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More

    The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.